Study: Medication for diabetes and weight loss can limit the risk of cancer

A new study indicated that the GLP-1 medicine used to treat diabetes and weight loss can have an effect associated with the risk of crops in its countries, which states that it usually reduces this risk, but it can sometimes increase it. The study included an overview of US researchers for medical records over ten years for 43 thousand and 317 users of this medicine and 43 thousand and 315 who did not take it. The GLP-1 medicine of “Novo Nordsk” for type 2 diabetes such as “Victoza” and “Ozimbek”, or the weight loss medicine “wigofi” and another of the “Eli Lily” business is “Monjo” to treat diabetes or “Zibound” to lose weight. All volunteers run the risk of obese cancer. The researchers told JAMA Oncology that 13.6 GLP-1 medicine users were diagnosed each year with one of the 14 types of cancer compared to 16.6 non-users. After observing individual factors, the total risk of cancer fell by 17% in GLP-1 drug users. Specifically, the intake of this medication is related to a decrease in the risk of endometrial cancer by 25%, ovarian cancer 47%and opinion crops 31%. GLP-1 medicine was also associated with a slight increase in the risk of kidney cancer. This increase was not statistically significant, which means it could be a coincidence. But the researchers said that a previous study also monitored an increase in the risk of kidney cancer with the use of GLP-1 medicine to treat diabetes. And such a study related to monitoring cannot prove the relationship and result ratio, and it is impossible to know if any decrease in the risk of cancer is the result of the GLP-1 medicine or the weight loss caused by the drug. However, the researchers said: “Since more than 137 million people in the United States can currently receive GLP-1 treatments, minor changes related to the risk of cancer have a major impact on public health.”